Published in Cancer Vaccine Week, November 10th, 2003
"Ghrelin, a newly described potent orexigenic peptide, may have therapeutic potential in patients with cachexia. We assessed whether pancreatic adenocarcinoma, commonly associated with marked cachexia, is a ghrelin-responsive malignancy," scientists in the United States report.
"Pancreatic adenocarcinoma cells were exposed to ghrelin (0-100 nM). Proliferation was determined by MTT assay. Ghrelin, ghrelin 1 a and 1b receptor expression, and Akt phosphorylation were assessed. The effects of ghrelin (its antagonist D-Lys-GHRP6, or the P13-K inhibitor Wortmannin) on cellular...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.